Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. (EPRX) generates a steady flow of news as a clinical-stage biotechnology company advancing drug candidates built on its Diffusphere™ drug delivery platform. Company updates focus on clinical data readouts, trial progress, financing events, and operational developments tied to its lead programs in eosinophilic esophagitis (EoE) and osteoarthritis.
A central theme in Eupraxia’s news is the RESOLVE trial for EP-104GI in EoE. Press releases detail Phase 1b/2a dose-escalation results, including tissue health outcomes measured by the EoE Histological Scoring System, symptom improvements via the Straumann Dysphagia Index, durability of response out to 52 weeks after a single administration, and safety and tolerability observations such as the absence of reported Serious Adverse Events and candidiasis in disclosed cohorts. Additional news covers the transition into and expansion of the randomized, placebo-controlled Phase 2b portion of RESOLVE and plans to increase patient numbers and dose levels.
Investors following EPRX news will also see pipeline and platform updates, including references to EP-104IAR for knee osteoarthritis and Eupraxia’s broader pipeline of long-acting formulations for inflammatory joint indications, oncology, and other potential disease areas. Financing announcements, such as public offerings of common shares under Canadian and U.S. prospectuses, provide context on how the company funds its clinical and preclinical programs, regulatory submissions, and manufacturing scale-up.
This news feed brings together clinical trial milestones, financial results, capital markets transactions, and conference participation disclosed by Eupraxia. Readers can use it to track how EP-104GI and EP-104IAR progress through development, how the Diffusphere™ platform is being applied across indications, and how management describes risk factors, cash runway, and strategic priorities over time.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 24-week symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. Cohort 9 (n=3) showed a mean SDI reduction of 4.0 points at 24 weeks (3 points = clinical remission).
Pooled cohorts 4-9 showed clinical remission in 59% at 12 weeks (13/22), 76% at 24 weeks (13/17), and 67% at 52 weeks (6/9). No SAEs reported across 31 patients and >220 patient-months; no oropharyngeal candidiasis observed.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q4 2025 results, highlighted by clinical progress in its lead program EP-104GI and strengthened liquidity from a Feb 20, 2026 public offering.
Key figures: net loss $16.7M for Q4 2025, cash $80.5M at Dec 31, 2025, and an offering that raised approximately $63.2M. Management expects funding into the second half of 2028.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced the closing of a public offering on Feb 20, 2026 raising approximately US$63.2 million gross from 7,607,145 common shares and pre-funded warrants, including full exercise of the underwriter option. Proceeds will fund EP-104GI clinical development, manufacturing, R&D and corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) priced a public offering on Feb 19, 2026 to raise approximately US$55 million through 6,428,574 common shares at US$7.00 and pre-funded warrants for up to 1,428,571 shares at US$6.99999 each.
The Offering includes a 30-day underwriter option for an additional 1,178,571 common shares and is expected to close on Feb 20, 2026, subject to TSX and Nasdaq listing approvals. Proceeds are earmarked primarily to advance EP-104GI clinical programs, expand indications, R&D, business development and general corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) filed a preliminary prospectus supplement on Feb 18, 2026 for a proposed public offering of common shares (or pre-funded warrants) and may grant underwriters a 30-day option for up to an additional 15% of the offering.
The company intends to use net proceeds primarily to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, manufacturing, and commercial readiness, plus additional GI indications, R&D, business development, IP expansion and general corporate purposes. Closing is subject to customary conditions and required TSX and Nasdaq approvals.
Leviathan Metals (OTC:LVXFF) agreed to sell the Timor Gold Project (EL006278) in Victoria, Australia to Au Gold Corp in exchange for CAD$75,000 cash (CAD$10,000 on signing, CAD$65,000 on closing) and 5,000,000 Au Gold shares, representing 11.16% ownership of Au Gold as of Jan 16, 2026. Timor covers 116.45 km2 and hosts historic high‑grade workings including Leviathan Mine (documented production 181,000 tonnes for 67,511 oz at 11.4 g/t Au).
The MPSA includes contingent cash consideration of $3.00 per ounce for any JORC or NI 43‑101 resources disclosed, payable within 90 days of public disclosure. Closing is subject to TSX Venture Exchange approval. Separately, Leviathan entered a marketing services agreement for C$260,000 through Oct 31, 2026 with optional renewals.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive tissue health and symptom data from the ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis. At 12 weeks the highest-dose cohort (8mg/site, 20 sites, n=3) showed near-complete tissue normalization (EoEHSS Grade -0.57 [94%], Stage -0.63 [97%]). Patients in 4mg/site cohorts (n=9) maintained 12-week improvements at 36 weeks (Grade -0.22, Stage -0.24). Among patients with ≥60% esophagus treated, clinical remission was 58% at 12 weeks (n=19), 79% at 24 weeks (n=14), and 67% at 52 weeks (n=6). Safety: >200 patient-months in 31 patients with no SAEs and no oral candidiasis reported.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported additional 52-week follow-up data from the Phase 1b/2a RESOLVE trial of a single administration of EP-104GI for eosinophilic esophagitis (EoE) on Nov 13, 2025.
Cohort 6 (n=3) showed durable symptom response at 52 weeks: all three maintained clinical benefit and two remained in clinical remission; combined Cohorts 5 and 6 had 4 of 6 patients in remission at 52 weeks. Week-36 remission across Cohorts 5–7 was 67% (n=9). Across >200 patient-months there were no serious adverse events and no oral or GI candidiasis. Plasma fluticasone levels remained predictable and well below typical daily asthma inhaler levels.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q3 2025 results and a business update on Nov 4, 2025. Key items: 52-week durable symptom and tissue responses observed after a single EP-104GI treatment (two-thirds of Cohort 5, N=3 remained in remission at 1 year).
The company closed an $80.5 million public offering (14,636,363 shares at $5.50) and held $89.0 million cash as of Sept 30, 2025, with a stated runway into the first half of 2028. Topline Phase 2b RESOLVE data expected by Q3 2026.
Operational notes: net loss of $6.4M for Q3 2025; management is monitoring potential impacts from proposed U.S.-Canada tariffs on supply chain and costs.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive clinical data from Cohort 9 of the RESOLVE trial for EP-104GI in Eosinophilic Esophagitis, testing the highest dose of 8mg per injection. The results showed significant improvements in tissue health outcomes and eosinophil reduction, with patients experiencing rapid clinical remission and maintaining long-term benefits.
Based on these promising results, the company plans to expand the Phase 2b portion of RESOLVE from 60 to at least 120 patients. The trial will use 8mg per injection with 20 injections per administration. Additionally, Eupraxia intends to broaden EP-104GI's development program by initiating trials for additional GI indications in H1 2026, including potential applications in fibrostenotic Crohn's, benign esophageal strictures, and Barrett's esophagus prevention.